Company Overview - Hesai Group (2525 HK) reported a strong performance in Q3, with GAAP earnings exceeding expectations and an upward revision of the full-year profit guidance [1][2] - The closing price was HKD 170.00, with a target price set at HKD 269.66, indicating a potential upside of 58.6% [1] Financial Performance - In the first three quarters of 2025, Hesai's revenue reached RMB 2.03 billion, representing a year-on-year increase of 49.3% [1] - Q3 revenue was RMB 800 million, showing a year-on-year and quarter-on-quarter growth of 47.5% and 12.6%, respectively [1] - The total shipment volume for the first three quarters was 989,311 units, with Q3 laser radar deliveries reaching 441,398 units, a significant year-on-year increase of 229% [1] Profitability Metrics - The gross margin for Q3 was 42.1%, slightly down by 0.4 percentage points quarter-on-quarter, maintaining an industry-leading position [2] - Net profit for Q3 was RMB 260 million, surpassing market expectations, partly benefiting from gains from the disposal of an early-stage tech company equity investment [2] - The full-year net profit guidance has been revised to a range of RMB 350 million to RMB 450 million [2] Market Outlook - The report emphasizes the importance of monitoring the progress of L3 autonomous driving regulations, which could accelerate the penetration of laser radar and increase the number of units per vehicle, serving as a catalyst for automotive components related to autonomous driving in the coming year [2] - Considering scale effects and Q3 performance, net profit forecasts for Hesai for 2025-2027 have been raised to RMB 410 million, RMB 460 million, and RMB 540 million, respectively [2] Valuation - A DCF valuation model maintains the target price at USD 34.66 / HKD 269.66, with a buy rating sustained [2]

Core Insights - The report highlights the focus on high-quality development in the real estate sector as outlined in the "14th Five-Year Plan" [1][2] - Preliminary data from CRIC indicates that the total sales of the top 100 developers increased by 4.0% month-on-month in October 2025, reaching 276.9 billion yuan [1] - The average selling price of properties decreased by 16.3% month-on-month, indicating a potential pricing pressure in the market [1] Real Estate Industry Summary - The sales volume of 21 major listed developers rose by 6.3% month-on-month in October, with sales area increasing by 10.2% [1] - Notable performers include Yuexiu Property and Vanke, both of which saw sales growth exceeding 50% month-on-month [1] - The price index for new residential properties in 70 major cities fell by 2.7% year-on-year and 0.4% month-on-month, while the second-hand residential price index dropped by 5.2% year-on-year and 0.6% month-on-month [1] Investment Opportunities - The report suggests that leading private enterprises may accelerate their debt restructuring processes as market sentiment improves [2] - Long-term investment outlook remains positive for China Resources Land and Yuexiu Property, both of which have demonstrated strong sales performance and execution capabilities in recent years [2]

Group 1: Technology Sector - Global technology stocks have experienced increased volatility, with the MSCI Information Technology Index rising by 5.6% from October 11 to November 10, outperforming the MSCI Global Index which increased by 3.4% [1] - The valuation of US technology stocks remains high, with the Shenyin Wanguo Electronics and Semiconductor Indexes showing a month-on-month price-to-earnings ratio change of -10% and +13% respectively [1] - Storage prices are expected to continue rising, with strong DRAM prices anticipated to last at least until Q3 2026, and NAND prices expected to remain robust until at least Q3 2026, an extension from previous expectations of H1 2026 [1] Group 2: Semiconductor Industry - In September, China's semiconductor manufacturing equipment imports reached $5.76 billion, marking a year-on-year increase of 35%, continuing a trend of significant growth for four consecutive months [2] - TSMC reported a 17% year-on-year revenue growth in October, indicating strong performance in the semiconductor sector [2] - Investment recommendations suggest focusing on domestic semiconductor equipment and core targets for domestic substitution, as AI infrastructure construction in both overseas and mainland China is expected to continue growing rapidly through 2026 [2] Group 3: Automotive Sector - In October, retail sales of passenger vehicles in China slightly decreased by 0.8% year-on-year, totaling 2.24 million units, while cumulative sales from January to October increased by 7.9% year-on-year to 19.25 million units [3][6] - The penetration rate of new energy vehicles (NEVs) reached 57.2% in October, with domestic brands increasing their market share to 70.8% in the NEV segment [3][6] - Passenger vehicle exports continued to show strong growth, with a total of 568,000 units exported in October, representing a year-on-year increase of 27.7% [4][6] - The share of new energy passenger vehicle exports rose to 44.2%, with 250,000 units exported, reflecting a year-on-year increase of 104% [4][6] - Investment insights suggest that the adjustment of new energy vehicle purchase tax exemptions in 2026 may stimulate consumer purchases towards the end of the year, maintaining high sales momentum [6]

Core Insights - The report highlights a strong growth trajectory for BeiGene (6160 HK) in Q3 2025, with product revenue reaching $1.41 billion, a year-on-year increase of 41% [1] - The sales of the drug Zebrutinib continued to show robust performance, with a quarterly sales increase of 51% and a year-on-year growth of 41%, amounting to $1.04 billion [1] - The company has raised its revenue guidance for 2025 to $5.1-5.3 billion, while also lowering its GAAP operating expense guidance to $4.1-4.3 billion [1] Revenue and Profitability - Q3 2025 gross margin improved by 3.1 percentage points to 86.0%, with SG&A and R&D expense ratios decreasing by 8.0 and 12.5 percentage points respectively [1] - Net profit for Q3 2025 expanded to $125 million, indicating a strong financial performance [1] Pipeline Developments - The report notes that BeiGene's pipeline is entering a critical phase, with 47 research abstracts selected for the ASH conference, including significant data from the 1L CLL Phase III SEQUOIA study [2] - Promising data for Bcl-2 sonrotoclax in various indications was presented, showing superior efficacy compared to Venetoclax, and a head-to-head study with Acala+Venetoclax is set to commence [2] - New products in solid tumors are expected to generate proof of concept data, with key focus on FGFR2b ADC, CEA ADC, and other combinations slated for Phase III trials [2] Target Price Adjustment - The target price for BeiGene has been raised to HKD 231, reflecting an increase in net profit forecasts by 3-52% [3]

Key Points - The report highlights that Huahong Semiconductor's 3Q25 gross margin exceeded expectations at 13.5%, compared to the forecast of 11.6% and previous guidance of 12% [1] - Revenue for 3Q25 was reported at $635 million, aligning with market expectations, while the management provided guidance for 4Q25 revenue between $650 million and $660 million [1] - The management anticipates that the 9A plant will reach a monthly capacity of 60,000 to 65,000 wafers by mid-2026 [1] - The average selling price (ASP) increased by over 5% quarter-on-quarter, attributed to price hikes across various platforms starting from 2Q25 [2] - The management noted strong downstream demand in the overall memory market, particularly for embedded NVM and independent NVM platforms [2] - Revenue forecasts for 2025, 2026, and 2027 have been adjusted to $2.4 billion, $2.84 billion, and $3.26 billion respectively, with gross margin estimates revised to 11.9%, 14.3%, and 16.8% [2] - The target price for Huahong Semiconductor has been slightly adjusted to HKD 91, corresponding to a 3.1x price-to-book ratio for 2026 [2]

Group 1: AMD (Advanced Micro Devices) - AMD's Q3 2025 revenue reached $9.25 billion, exceeding both the firm's and market expectations, with a Non-GAAP gross margin of 54%, aligning with prior forecasts [1][2] - The company provided guidance for Q4 2025, projecting a median revenue of $9.6 billion (±$300 million) and a gross margin of approximately 54.5%, both surpassing previous estimates [1][2] - AMD's revenue forecasts for 2025, 2026, and 2027 have been raised to $33.99 billion, $44.69 billion, and $59.54 billion respectively, with Non-GAAP EPS estimates adjusted to $4.49, $6.51, and $9.23 [2] Group 2: Youdao (DAO US) - Youdao is expected to continue focusing on high school education, AI, and advertising, with ad revenue anticipated to accelerate due to AI technology and new customer expansion [3] - The company is adjusting its profit expectations for the year, as increased investments in advertising and high school business may impact short-term profit trends, but long-term growth potential remains strong [3] - The target price for Youdao is maintained at $12.00, indicating a potential upside of 14.3% from the current price of $10.50 [3] Group 3: XPeng Motors - XPeng Motors held its 2025 Technology Day, unveiling significant advancements in "physical AI," including the second-generation VLA model and Robotaxi initiatives [5][6] - The second-generation VLA is set to be implemented in the XPeng Ultra model by Q1 2026, with Volkswagen confirmed as the first customer [5] - XPeng plans to launch three Robotaxi models in 2026, collaborating with Gaode for global ecosystem partnerships [6] Group 4: Economic Data - Upcoming economic data releases include the Manufacturing Purchasing Managers' Index (PMI) for October in the US, with a market expectation of 52.20, and the ISM Non-Manufacturing PMI, expected at 50.00 [7] - The data will provide insights into the economic conditions and potential impacts on various sectors [7]

Investment Rating - The report assigns a "Buy" rating for Advanced Micro Devices (AMD US) with a target price raised to $275 from $248, indicating a potential upside of 10% from the current price of $250.05 [4][17]. Core Insights - AMD's 3Q25 performance exceeded expectations, with revenue of $9.246 billion and a Non-GAAP gross margin of 54%. The guidance for 4Q25 is also optimistic, with a revenue midpoint of $9.6 billion and a gross margin of approximately 54.5% [2][7]. - The report highlights strong performance in the data center CPU segment, driven by the successful rollout of the MI350 series and increasing demand for AMD's CPU products, particularly in the context of AI data center expansion [7][10]. - The forecast for AMD's revenue and earnings per share (EPS) has been revised upwards for 2025, 2026, and 2027, reflecting a more optimistic outlook on data center CPU revenue and recovery in gaming demand [7][10]. Financial Overview - Revenue projections for AMD are as follows: - 2023: $22.68 billion - 2024: $25.785 billion - 2025E: $33.995 billion - 2026E: $44.686 billion - 2027E: $59.541 billion - The expected growth rates are 13.7% in 2024, 31.8% in 2025, 31.5% in 2026, and 33.2% in 2027 [3][18]. - Non-GAAP EPS is projected to grow from $2.65 in 2023 to $9.23 in 2027, with significant year-on-year increases [3][18]. Market Position and Strategy - AMD is focusing on expanding its market share in the data center segment, particularly with the introduction of new products like the MI450 series, which is expected to contribute significantly to revenue in 2026 and beyond [10][11]. - The collaboration with OpenAI is seen as a critical factor for AMD's growth, providing opportunities to secure large orders from major cloud service providers and enhance its competitive position in the industry [8][10]. Stock Performance - AMD's stock has shown a significant increase of 107.01% year-to-date, reflecting positive market sentiment and performance expectations [6]. - The stock's 52-week high is $264.33, while the low is $78.21, indicating substantial volatility and potential for growth [6].

Core Insights - The pharmaceutical sector showed signs of marginal recovery in Q3 2025, with a focus on academic conferences, policy changes, and business development catalysts expected in Q4 2025 [1][2] - The Hong Kong pharmaceutical market experienced a pullback in October due to sentiment decline and profit-taking, but the underlying fundamentals remain strong, with an anticipated stabilization in investment sentiment starting November [2] Market Performance - The Hang Seng Healthcare Index fell by 1.3% this week, outperforming the broader market, with traditional Chinese medicine, biopharmaceuticals, and distribution sectors showing better performance [1] - Domestic institutions increased their positions in high-value innovative drug targets, medical device companies, and service-oriented firms, particularly those benefiting from interest rate cuts and downstream demand recovery [1] Investment Recommendations - Focus on innovative drugs such as Sanofi and Deqi Pharmaceuticals, which have rich short-term catalysts and valuations that do not yet reflect the value of core products; companies like Xiansheng Pharmaceuticals, Hutchison China MediTech, and Legend Biotech are significantly undervalued with clear long-term growth logic [2] - In the CXO sector, leading firms benefiting from high downstream demand and marginal financing recovery are recommended, such as WuXi AppTec [2]

Investment Rating - The report assigns a "Buy" rating to New Oriental Education Technology (9901 HK) with a target price of HKD 55.00, indicating a potential upside of 19.9% from the current price of HKD 45.88 [4][8][15]. Core Insights - The report highlights that K12 education may accelerate, boosting shareholder returns and enhancing confidence in the company's growth prospects [2]. - Financial forecasts indicate a revenue growth trajectory, with expected revenues of USD 4.9 billion in 2025, growing to USD 6.875 billion by 2028, reflecting a compound annual growth rate (CAGR) of approximately 12% [3][16]. - The net profit is projected to increase from USD 372 million in 2025 to USD 792 million by 2028, with a notable increase in earnings per share (EPS) from USD 0.32 in 2025 to USD 0.45 in 2028 [3][16]. Financial Overview - Revenue (in million USD) is forecasted as follows: - 2024: 4,314 - 2025: 4,900 - 2026E: 5,413 - 2027E: 6,136 - 2028E: 6,875 - Year-on-year growth rates are expected to be 43.9% in 2024, 13.6% in 2025, and gradually declining to 12.0% by 2028 [3][16]. - Net profit (in million USD) projections are: - 2024: 310 - 2025: 372 - 2026E: 428 - 2027E: 481 - 2028E: 792 [3][16]. Valuation - The report employs a Sum-of-the-Parts (SOTP) valuation method, assigning a price-to-earnings (P/E) ratio of 15x for K12 business and 8x for study abroad business, reflecting expected profit growth rates of +25% and -7% respectively [7][8]. - The target price was adjusted upwards to HKD 55.00 from a previous HKD 46.00, maintaining a "Buy" rating based on the strong demand and growth outlook for K12 education services [7][8].

Group 1: New Oriental Education Technology - The company reported a revenue increase of 6% year-on-year to $1.523 billion for Q1 FY2026, exceeding expectations by 1% [1] - Adjusted operating profit was approximately $336 million, with an operating margin of 22%, expanding by 1 percentage point year-on-year [1] - The management maintained the revenue guidance for FY2026, expecting a growth rate of 5-10%, with Q2 revenue growth projected between 9-12% [1][2] - The company announced a cash dividend of $190 million and a share buyback plan of $300 million, which is better than previous expectations [1] Group 2: Howie Group - Howie Group achieved a record high quarterly performance in Q3 2025, with revenue of 7.83 billion yuan, a year-on-year increase of 14.8%, and a net profit of 1.18 billion yuan, up 17.3% [3] - The gross margin for Q3 was 30.3%, reflecting a 0.3 percentage point increase quarter-on-quarter [3] - The growth in the automotive CIS segment is expected to drive revenue growth, with increasing demand in smart driving applications [4] Group 3: Valuation and Market Outlook - The valuation outlook for New Oriental's K12 education business remains positive due to steady revenue growth and potential for margin optimization [2] - The target price for New Oriental has been raised to HKD 55.00, reflecting a potential upside of 19.9% [1][2] - Howie Group's target price is maintained at 180 yuan, corresponding to a 35 times P/E ratio for 2026 [4]